Plain-English translation of NCT05739864 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing fecal microbiota transplantation () — a treatment where material from a carefully selected healthy donor is transferred into your digestive system — to see if it can help people with mild-to-moderate ulcerative colitis go into remission. The researchers will compare the treatment to a placebo (an inactive version) to see which works better. Previous research suggests this approach may be very effective, but this is the first study to test it specifically in ulcerative colitis patients.
Ulcerative colitis causes painful inflammation in the colon, and current treatments don't work for everyone. Early evidence suggests that restoring healthy bacteria in the gut using material from a specially selected donor might help, but we need to test this carefully in people with ulcerative colitis to know if it really works.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the donor treatment or a placebo version. Researchers will monitor changes in your symptoms, collect blood samples, and assess your gut bacteria at different timepoints. The study will track your disease activity using a standardized scoring system and examine how the treatment affects your immune response and microbiome over time.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Italy